Get the Stockscreener App
0.9781
7.73%
-0.0819
After Hours:
.99
0.0119
+1.22%
Citius Oncology Inc stock is traded at $0.9781, with a volume of 181.31K.
It is down -7.73% in the last 24 hours and down -1.20% over the past month.
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.
See More
Previous Close:
$1.06
Open:
$1.09
24h Volume:
181.31K
Relative Volume:
0.10
Market Cap:
$69.74M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-11.88%
1M Performance:
-1.20%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$0.9734
$1.09
1-Week Range:
$0.95
$1.195
52-Week Range:
$0.85
$2.87
Citius Oncology Inc Stock (CTOR) Company Profile
Name
Citius Oncology Inc
Sector
Phone
(347) 627-0058
Address
420 LEXINGTON AVE,, NEW YORK
Compare CTOR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTOR
Citius Oncology Inc
|
0.9781 | 69.74M | 0 | 0 | 0 | 0.00 |
|
ZTS
Zoetis Inc
|
164.84 | 74.37B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.69 | 43.81B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.10 | 41.53B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
22.09 | 25.03B | 16.77B | -959.00M | 1.37B | -0.85 |
|
VTRS
Viatris Inc
|
12.52 | 14.94B | 15.05B | -883.30M | 1.89B | -0.74 |
Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-27-24 | Initiated | Maxim Group | Buy |
Citius Oncology Inc Stock (CTOR) Latest News
Major Improvements In Citius Oncology Inc (CTOR) Stock Need To Be Considered - Stocks Register
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology - The Eastern Progress Online
“Market Movers: CTOR, CTNT, PNPN.V, KITT, SHIM – More Stocks Inside To Watch” - Barchart
Maxim Group Begins Coverage on Citius Oncology (NASDAQ:CTOR) - Defense World
Loss-Making Citius Oncology, Inc. (NASDAQ:CTOR) Expected To Breakeven In The Medium-Term - Simply Wall St
Citius Oncology, Inc.'s (NASDAQ:CTOR) Path To Profitability - Yahoo Finance
Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution - Marketscreener.com
Citius Pharmaceuticals Engages Financial Advisor for Oncology Subsidiary Spinoff - Marketscreener.com
Citius Pharma Advances Mino-Lok After Successful FDA Meeting, Phase 3 Trial Results | CTXR Stock News - StockTitan
CTOR stock touches 52-week low at $0.9 amid market challenges - Investing.com Canada
CTOR stock touches 52-week low at $0.9 amid market challenges By Investing.com - Investing.com South Africa
Citius Pharmaceuticals Announces 1-for-25 Reverse Stock Split to Maintain Nasdaq Listing | CTXR Stock News - StockTitan
Citius Pharmaceuticals reports positive early stage results of cancer combo treatment - MSN
Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering - BioSpace
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering - BioSpace
Citius Pharmaceuticals Raises $3M in Direct Offering at $0.25 Per Share with Warrants | CTXR Stock News - StockTitan
Citius Pharmaceuticals Raises $3M in Direct Offering at $0.25 Per Share | CTXR Stock News - StockTitan
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors - BioSpace
Citius' LYMPHIR Shows Potential To Boost Pembrolizumab Efficacy - Contract Pharma
CTOR stock touches 52-week low at $1.02 amid market challenges - Investing.com India
CTOR stock touches 52-week low at $1.02 amid market challenges By Investing.com - Investing.com South Africa
CTOR stock touches 52-week low at $1.29 amid market challenges By Investing.com - Investing.com South Africa
CTOR stock touches 52-week low at $1.29 amid market challenges - Investing.com
Citius Pharmaceuticals stock hits 52-week low at $0.48 - Investing.com
Citius Oncology (NASDAQ:CTOR) Stock Quotes, Forecast and News Summary - Benzinga
CTMX stock rated an Overweight by Piper Sandler - Knox Daily
CTOR Stock Update: Citius Oncology Inc.’s Banking’s Market Struggles and Potential Opportunities - The InvestChronicle
Investor’s Delight: Cytek BioSciences Inc (CTKB) Closes Strong at 5.19, Up 1.96 - The Dwinnex
Cytek BioSciences Inc (CTKB)’s stock performance: a year in review - US Post News
Check Out Citius Pharmaceuticals Inc (CTXR)’s Trade Data Rather Than the Analysts’ Views - SETE News
CTXR’s price-to-book ratio: An indicator of the company’s performance - US Post News
Ciena Stock Goes to Buy From Sell at Citi. Here’s Why. - Barron's
Closing Strong: Citius Oncology Inc. (CTOR) Ends at 1.60, Down -4.19 from Last Close - The Dwinnex
XTX Topco Ltd Acquires 15,997 Shares of Catalent, Inc. (NYSE:CTLT) - Defense World
CTOR stock touches 52-week low at $1.51 amid market challenges - Investing.com Canada
CitiusTech to pursue acquisitions, shifts hiring strategy on GenAI push - TechCircle
Citius Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement - Quantisnow
Citius Pharmaceuticals faces potential Nasdaq delisting - Investing.com
NCCN Adds Denileukin Diftitox to CTCL Clinical Practice Guidelines in Oncology - OncLive
Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Kilgore News Herald
Citius Pharmaceuticals Announces Closing of $15 Million Registered Direct Offering - Quantisnow
A stock that deserves closer examination: Citius Oncology Inc. (CTOR) - US Post News
Daily Market Movement: Citius Oncology Inc. (CTOR)’s financial ratios: A comprehensive overview - The Dwinnex
CTOR stock touches 52-week low at $1.67 amid market challenges - Investing.com
Citius Oncology Inc. (CTOR) requires closer examination - US Post News
Citius Pharmaceuticals selloff since spinout an opportunity, says EF Hutton - TipRanks
CTOR’s Market Whiplash: -81.72% YTD Decline, -82.47% Plunge in 30 Days - The InvestChronicle
Citius Oncology Inc Stock (CTOR) Financials Data
There is no financial data for Citius Oncology Inc (CTOR). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.61%
1.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):